Literature DB >> 26084611

Specific combinations of the chromatin-modifying enzyme modulators significantly attenuate glioblastoma cell proliferation and viability while exerting minimal effect on normal adult stem cells growth.

Arshak R Alexanian1, Yi-Wen Huang2,3.   

Abstract

The discoveries of recent decade showed that all critical changes in cancer cells, such as silencing of tumor-suppressor genes and activation of oncogenes, are caused not only by genetic but also by epigenetic mechanisms. Although epigenetic changes are somatically heritable, in contrast to genetic changes, they are potentially reversible, making them good targets for therapeutic intervention. Covalent modifications of chromatin such as methylation and acetylation of histones and methylation of DNA are the important components of epigenetic machinery. In this study, we investigated the effect of different modulators of DNA and histone covalent-modifying enzymes on the proliferation and viability of normal adult stem cells, such as human bone marrow mesenchymal stem cells (hMSCs), and on malignant tumor cells, such as glioblastoma (GB) D54 cells. Results demonstrated that specific combinations of histone methyltransferases and deacetylases inhibitors significantly attenuated D54 cells viability but having only a small effect on hMSCs growth. Taken together, these studies suggest that specific combinations of histone covalent modifiers could be an effective treatment option for the most aggressive type of primary brain tumors such as glioblastoma multiforme.

Entities:  

Keywords:  Chromatin; DNA methylation; Epigenetic; Glioblastoma; Stem cells

Mesh:

Substances:

Year:  2015        PMID: 26084611     DOI: 10.1007/s13277-015-3654-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

Review 1.  Epigenetic therapy of cancer: past, present and future.

Authors:  Christine B Yoo; Peter A Jones
Journal:  Nat Rev Drug Discov       Date:  2006-01       Impact factor: 84.694

2.  Epigenetic modulators promote mesenchymal stem cell phenotype switches.

Authors:  Arshak R Alexanian
Journal:  Int J Biochem Cell Biol       Date:  2015-04-29       Impact factor: 5.085

Review 3.  The epigenomics of cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Cell       Date:  2007-02-23       Impact factor: 41.582

4.  EZH2 is essential for glioblastoma cancer stem cell maintenance.

Authors:  Mario-Luca Suvà; Nicolò Riggi; Michalina Janiszewska; Ivan Radovanovic; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Marie-Aude Le Bitoux; Denis Marino; Luisa Cironi; Victor E Marquez; Virginie Clément; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 5.  DNA methyltransferase inhibitors for cancer therapy.

Authors:  Bodo Brueckner; Dirk Kuck; Frank Lyko
Journal:  Cancer J       Date:  2007 Jan-Feb       Impact factor: 3.360

6.  Expression profile of class I histone deacetylases in human cancer tissues.

Authors:  Masamune Nakagawa; Yoshinao Oda; Takashi Eguchi; Shin-Ichi Aishima; Takashi Yao; Fumihito Hosoi; Yuji Basaki; Mayumi Ono; Michihiko Kuwano; Masao Tanaka; Masazumi Tsuneyoshi
Journal:  Oncol Rep       Date:  2007-10       Impact factor: 3.906

7.  Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.

Authors:  Hong Tao; Haiying Li; Yanhuang Su; Danni Feng; Xilong Wang; Chun Zhang; Hui Ma; Qikuan Hu
Journal:  Mol Cell Biochem       Date:  2014-05-16       Impact factor: 3.396

8.  Beyond Genetics in Glioma Pathways: The Ever-Increasing Crosstalk between Epigenomic and Genomic Events.

Authors:  Ramón Martínez
Journal:  J Signal Transduct       Date:  2012-06-18

9.  EHMT2 inhibitor BIX-01294 induces apoptosis through PMAIP1-USP9X-MCL1 axis in human bladder cancer cells.

Authors:  Jing Cui; Wendong Sun; Xuexi Hao; Minli Wei; Xiaonan Su; Yajing Zhang; Ling Su; Xiangguo Liu
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

10.  Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer.

Authors:  Fernanda S Giudice; Decio S Pinto; Jacques E Nör; Cristiane H Squarize; Rogerio M Castilho
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

View more
  2 in total

1.  Unique combinations of epigenetic modifiers synergistically impair the viability of the U87 glioblastoma cell line while exhibiting minor or moderate effects on normal stem cell growth.

Authors:  Arshak R Alexanian; Avonlea Brannon
Journal:  Med Oncol       Date:  2022-04-28       Impact factor: 3.064

2.  Emerging targets for glioblastoma stem cell therapy.

Authors:  Ahmad R Safa; Mohammad Reza Saadatzadeh; Aaron A Cohen-Gadol; Karen E Pollok; Khadijeh Bijangi-Vishehsaraei
Journal:  J Biomed Res       Date:  2015-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.